SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and

PALISADE Phase 3 Program focused on acute treatment of anxiety in adults with Social Anxiety Disorder FDA Fast Track designation granted Topline results anticipated in mid-2022 SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics Inc.

SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system

Ann Cunningham has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing, and global life cycle product management expertise for many successful branded product campaigns for large pharmaceutical companies SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE

Dr. Curley brings extensive pharmaceutical industry experience in product development, commercialization and operations as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- 

SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and

PH10 may have stand-alone potential to displace current oral antidepressants in the drug treatment paradigm for depression disorders SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and

Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD) Strengthened Balance Sheet upon closing of $100 million underwritten public offering SOUTH SAN

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous